



The 15th Asia Partnership Conference of Pharmaceutical Associations



PROGRAM

Date: April 21 (Tuesday), 2026

Venue: Keidanren Kaikan

Greeting

Nobuo Murakami

We welcome everyone who is contributing to people's health in Asia through the development of innovative medicines and technologies. APAC has been inviting all stakeholders of the healthcare ecosystem, including members of pharmaceutical manufacturers associations, regulatory authorities and health ministries, academia, and healthcare professionals.



This is the 15th APAC Conference, and we are meeting both in person and online.

On this milestone occasion, we are proud to share our updated Mission and Image Diagram. Our Mission is: "Enhancing access to innovative medicines for the people in Asia." This reflects our stronger commitment than ever to bringing innovative medicines to patients across Asia, and our updated Image Diagram illustrates how this can be achieved through activities across the entire value chain.

We are also delighted to welcome the Pharma Group in Vietnam as a new official member of APAC this year. We now have 14 pharmaceutical associations, and this is a significant step in further strengthening our network across Asia.

While there are differences in medical supply systems, including social infrastructure and health insurance systems, improving access to innovative medicines is a common challenge for all countries. By fostering strong relationships and partnerships, we strongly believe that APAC activities can leverage the strengths and resources of various stakeholders to realize our mission.

We look forward to your active participation and engaging discussions to deepen our collaboration and achieve our mission. Thank you for being part of this important conference. Let us come together to shape the future of pharmaceuticals in Asia.

Chairperson APAC steering committee
& JPMA APAC management committee

The 15th Asia Partnership Conference of Pharmaceutical Associations (APAC)

Program

Clock Time (JST)	Time Required	Session contents	Chair/Speaker/Panelist	
08:45 ▶ 09:00	15	Come-in		
09:00 ▶ 09:05	5	Opening Remarks	Asuka Miyabashira	JPMA
09:05 ▶ 09:15	10	Congratulatory Speech	David Reddy	IFPMA
09:15 ▶ 09:30	15	Keynote Speech	Yasuhiro Fujiwara	PMDA
09:30 ▶ 09:45	15	< Group Photo & Break >		
09:45 ▶ 11:35	110	RA Session: Optimizing Reliance Pathways across the Product Lifecycle: ~ Exploring Best Practices to Enhance Predictability and Consistency ~		
		Chair	Ayumi Endo Masaaki Kanno	PMDA JPMA
09:45 ▶ 09:55	10	WHO Good Reliance Practices throughout the life cycle to facilitate access to quality-assured medical products globally	Marie Valentin	WHO
09:55 ▶ 10:10	15	Reliance Pathways in APAC: Current Adoption, Challenges, and Opportunities for Optimization	Sannie Chong	APAC RA-EWG
10:10 ▶ 10:25	15	Experience in Implementing Reliance Pathways for NDA and PAC	Jesusa Joyce Cirunay	Philippines FDA
10:25 ▶ 10:40	15	Optimizing Reliance Pathways Across the Product Lifecycle: Exploring Best Practices to Enhance Predictability and Consistency	Choo Qiuyi	HSA
10:40 ▶ 11:23	43	Panel Discussion	Shinichi Noda Athiporn Doomkaew Ria Christine Siagian Rosliza Lajis Siew Mei Long	Speakers plus: PMDA Thai FDA BPOM NPRA RA-EWG
10:23 ▶ 11:33	10	Audience Live-Q		
11:33 ▶ 11:35	2	Closing		
11:35 ▶ 11:40	5	< Preparation (NOT break) >		
11:40 ▶ 12:10	30	DA Session: Reflecting on DA-EWG Contributions and Achievements		
		Chair	Megumi Ikemori	JPMA
11:40 ▶ 12:10	30	Our Journey : Comprehensive Review and Strategic Outlook	Jun Terauchi Megumi Ikemori	Japan Microbiome Consortium (JMBC) / Metagen Therapeutics Inc. JPMA
12:10 ▶ 13:00	50	< Lunch Break >		
13:00 ▶ 14:50	110	e-labeling Session: Empowering Patients Through e-labeling: Bridging Digital Health and Accessible Information		
		Chair	Chih-Kang Chiang Rie Matsui	Taiwan FDA JPMA
13:00 ▶ 13:05	5	Opening	Rie Matsui	JPMA
13:05 ▶ 13:15	10	E-labeling Pilot Project Update - Indonesia Case Study	Erlina Widianty Pratiwi	BPOM
13:15 ▶ 13:25	10	The QUEST for Interoperability: Malaysia's Strategic Roadmap from PDF to FHIR-READY XML	Kobu Thiruvanackan	NPRA
13:25 ▶ 13:35	10	E-Labeling in Taiwan: Implementation Status and Future Directions	Miao-Ju Chien	Taiwan FDA

Clock Time (JST)	Time Required	Session contents	Chair/Speaker/Panelist	
13:35 ▶ 13:45	10	E-Labeling : Current Status and Next Steps in Japan	Miki Ota	PMDA
13:45 ▶ 14:45	60	Panel Discussion Audience Live-Q	Dorothy Toh Nguyen Van Loi Nada Kim Kharlo De Guzman Worasuda Yoongthong Shimon Yoshida	All speakers plus: HSA DAV MFDS Philippines FDA Thai FDA International Advisory Board Member for IMI IMI Gravitate Health, Pfizer
14:45 ▶ 14:50	5	Closing	Chih-Kang Chiang	Taiwan FDA
14:50 ▶ 15:00	10	< Break >		
15:00 ▶ 16:30	90	MQS Session: Advanced Technologies		
		Chair	Nobuhiro Shimizu Keiichi Kodama	PMDA JPMA
15:00 ▶ 15:10	10	Opening & Introduction	Ikuo Kushida	JPMA
15:10 ▶ 15:30	20	Advanced Technologies: Artificial Intelligence (AI) / Machine Learning (ML) in Pharmaceutical Manufacturing	Lim Na	HSA
15:30 ▶ 15:50	20	Application of Artificial Intelligence in Pharmaceutical Manufacturing	Srinivasan Kellathur	PhAMA
15:50 ▶ 16:10	20	Implementation of Advanced Technologies in Pharmaceutical Manufacturing in Japan	Nobuhiro Shimizu	PMDA
16:10 ▶ 16:25	15	Panel Discussion	Kentaro Hara Yuki Marumo	Speakers plus: PMDA PMDA
16:25 ▶ 16:30	5	Closing	Keiichi Kodama	JPMA
16:30 ▶ 16:40	10	< Break >		
16:40 ▶ 18:20	100	aUHC Session: Realizing True UHC in Asia through Hybrid Financing Models		
		Chair	Toshihiko Takeda	Boston Consulting Group
16:40 ▶ 16:45	5	Toward the Achievement of True UHC in Asia	Toshihiko Takeda	Boston Consulting Group
16:45 ▶ 17:05	20	Public Private Partnership (PPP) Opportunities in Healthcare & Pharma - Perspectives & Learnings from India	G. N. Singh	Office of Hon'ble CM, Govt of Uttar Pradesh
17:05 ▶ 17:25	20	The Evolution from Commercial Insurance to PPP policies	Alex Xia	Shanghai Shuisai Technology Co., Ltd.
17:25 ▶ 17:45	20	Beyond Oncology—UHC as a Driver for Health Equity	Lian-yu Chen	Taiwan NHIA
17:45 ▶ 18:15	30	Panel Discussion		All speakers
18:15 ▶ 18:20	5	Wrap-up and Closing Remarks	Toshihiko Takeda	Boston Consulting Group
18:20 ▶ 18:25	5	Closing Remarks	Sunao Manabe	JPMA
18:30 ▶ 20:00	90	Reception		Onsite Participants

Opening Remarks

Asuka Miyabashira

President
Japan Pharmaceutical Manufacturers Association (JPMA)

Asuka Miyabashira is President of Japan Pharma Business Unit of Takeda Pharmaceutical Co., Ltd. She joined Takeda in 2004 and has served in roles of increased responsibility in marketing and medical in Japan and other countries. Her experiences include leading regional sales in Japan as well as important international assignments, such as country manager at Takeda Vietnam, where she led the development of the local business strategy and transformation. Prior to this role, she served as business operation manager at Takeda Indonesia to build the foundation for Takeda Oncology's new product launch and access strategy. She served as the head of the Neuroscience Business Unit within JPBU for two years before the appointment to her current role. She has been appointed as a President of JPMA since May 2025. Asuka holds an MSc in Agriculture from Kyushu University, Japan.



Closing Remarks

Sunao Manabe

Vice President
Japan Pharmaceutical Manufacturers Association (JPMA)

Sunao Manabe is Executive Chairperson of Daiichi Sankyo Co., Ltd. He previously served as President and COO from 2017 to 2019, as President and CEO from 2019 to 2023 and as Executive Chairperson and CEO from 2023 to March 2025.

Dr. Manabe began his career at Sankyo Co., Ltd as a researcher in 1978. He has been involved in various areas, including R&D, general affairs & human resources, corporate strategy, and global sales & marketing, in Daiichi Sankyo.

Additionally, he has been appointed as Vice President of Japan Pharmaceutical Manufacturers Association since May 2021. He also served as Vice President of International Federation of Pharmaceutical Manufacturers & Association from January 2023 to March 2025.

Dr. Manabe received DVM degree in 1977 and PhD degree in 1988 from Veterinary Science, the University of Tokyo. He also obtained an MS degree in Medical Sciences from the University of Tsukuba in 1982. Also, he was based in the Ohio State University from 1988 to 1990 as a visiting scientist of College of Veterinary Medicine.



Congratulatory Speech

David Reddy

Director General

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

David Reddy joined IFPMA as Director General in April 2024, taking up the post after 13 years as Chief Executive of the Medicines for Malaria Venture (MMV).

At the Medicines for Malaria Venture, David played a pivotal role as the organization established the largest portfolio of malaria drugs ever assembled, bringing forward 15 medicines that have saved more than 15 million lives. David has been a Board Member of the Coalition for Epidemic Preparedness (CEPI) since 2018 and serves on the Board of Malaria No More UK.

Before joining MMV, David was a Vice President at Roche, where he held corporate responsibility for Roche's response to the 2009/2010 influenza pandemic. In this role, he led the work to develop, communicate, and implement the company's strategy for working with governments and the WHO on pandemic preparedness, and establishing a sustainable access program. Prior to this, he led Roche's HIV/AIDS Disease Area Strategy Team, providing strategic leadership for Roche's HIV portfolio.

David holds a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand and completed a post-doctoral fellowship in molecular neurobiology at the Friedrich-Miescher Institute in Basel, Switzerland. David has more than 30 years of management experience in the healthcare sector, including leadership of drug development teams including working on anti-viral diagnostics, a recombinant vaccine, and novel antiviral strategies; licensing and alliance management; market analytics and business planning; product and disease area management; and interfacing with governments, NGOs, and patient advocacy groups in priority disease areas.



Keynote Speech

Yasuhiro Fujiwara

Chief Executive

Pharmaceuticals and Medical Devices Agency (PMDA)

Dr Yasuhiro Fujiwara is Chief Executive of the PMDA since 2019. He actively engages with international regulatory agencies, including the International Coalition of Medicines Regulatory Authorities (ICMRA) in which he served as vice-chair 2019 to 2025. Under his strong leadership, PMDA has promoted collaboration with Asian regulatory authorities.

A medical oncologist specializing in breast cancer, Dr Fujiwara was previously Director-General of the Strategic Planning Bureau of the National Cancer Center, and Deputy Director of National Cancer Center Hospital. Between Jan 2011 to Feb 2013, he was a Deputy Secretary General of the Office of Medical Innovation, Cabinet Secretariat of Japan, and led health policy issues regarding life science.

Dr Fujiwara has authored or co-authored over 280 original articles in peer-reviewed journals. He is an active member of the American Society of Clinical Oncology and serves on the editorial board of some journals.



RA Session

Overview

RA-EWG Masaaki Kanno

Optimizing Reliance Pathways across the Product Lifecycle: ~ Exploring Best Practices to Enhance Predictability and Consistency ~

This RA Session explores how review reliance can be implemented more predictably and consistently across the product lifecycle with a focus on both NDA and PACs. Drawing on the recent APAC Survey, the session will compare the challenges of PAC reliance with those encountered in NDA reliance, examining why PAC reliance remains more challenging despite progress in NDA pathways, and what minimum conditions are needed for reliance to deliver real efficiency and timely patient access.

Chair

Ayumi Endo

Office Director
Office of Asia Training Center and International Cooperation

Ms. Endo oversees the Asia Training Center and international cooperation activities at PMDA and is responsible for planning and implementing training programs for overseas regulatory authorities. She has been actively promoting regulatory harmonization and inter-agency cooperation, particularly with Asian countries. During her nearly 20 years at PMDA, she has served in new drug review and consultation, and post-marketing drug safety operations. She has led one of the ICH working groups to develop a guideline and supported domestic implementation. She also has prior research experience in the pharmaceutical industry. She holds a Master of Pharmacy from Kyoto University.



Chair

Masaaki Kanno

Leader of APAC RA-EWG
Otsuka Pharmaceutical Co., Ltd.

Joined Otsuka Pharmaceutical Co., Ltd. at Regulatory Affairs Department since Oct. 2019, and works now as a leader of Asia Regulatory Team in the said department. He is also the leader of RA Expert Working Group of APAC since May, 2025. He is also one of the co-authors for the APAC Paper (<https://rdcu.be/d3OXr>) which provides key findings on regulatory agility, reliance, digital transformation, and regional collaboration.



Speaker / Panelist

Marie Valentin

Senior Technical Officer, Special Access Programme, Office of the Regulation and Safety Unit [REG]
Regulation and Prequalification Department [RPQ]
Health Systems, Access and Data (HSD) Division
World Health Organization



Pharmacist specialized in drug product regulation with over 24 years of experience in regulatory affairs and product development, acquired both in the private and public sectors.

Since September 2023, Marie leads the activities of the Special Access Programme supporting the Member States in implementing various facilitated pathway, including collaborative procedures, reliance approaches, and joint activities to facilitate and accelerate the introduction of priority medical products in countries. She previously worked in the WHO Regulatory Convergence and Networks Team towards convergence, harmonization, reliance and system strengthening activities.

Before joining WHO in May 2019, Marie worked for 9 years at the European Medicines Agency in London as a Regulatory Affairs Officer. Before that, she worked in the pharmaceutical industry, contract research organization and consultancies in the United Kingdom, Spain and France.

Speaker / Panelist

Sannie Chong

Asia Pacific Lead
Merck Sharp & Dohme (MSD)



Since Aug 2022: **Asia Pacific Lead, Merck Sharp & Dohme (MSD)**

- Lead for 2022, 2024 and 2026 APAC paper publication
- Chair, EFPIA Korea-Taiwan Network
- IFPMA ICH Group

2014 – 2022: **Asia Pacific Regulatory Policy Lead, Roche**

- APEC Regulatory Harmonisation Steering Committee (RHSC): Lead for 2018 and 2021 convergence KPIs paper publication
- APEC RHSC: Biotherapeutics Sub-Champion

2003 – 2014: **Director, Health Sciences Authority of Singapore** Represented Singapore in:

- The WHO prequalification program
- The ASEAN Pharmaceutical Products Working Group
- The Australia-Canada-Singapore-Switzerland (ACSS) Consortium for work-sharing initiatives.

Speaker / Panelist

Jesusa Joyce Cirunay

Director IV
Food and Drug Administration




JESUSA JOYCE N. CIRUNAY is currently the Director IV of the International Regulatory Operations Policy Committee at the Office of the Director General, Food and Drug Administration Philippines. She is a Registered Pharmacist (cum laude) with graduate studies in Pharmaceutical Science at the Vrije Universiteit van Brussel in Belgium. Her government service began at the Product Services Division (PSD) covering Marketing Authorizations as Pharmaceutical Researcher then as Senior Drug Evaluator including New Drug Applications and Vaccines. Before her current post, she was assigned to head several key offices of the Agency at various timelines, i.e., OIC-DDG, Field Regulatory Operations Office; Director IV, Center for Drug Regulation and Research; Field Cluster Director II in various parts of the Philippines, as Head of the GMP Inspectorate; as Head of the Distribution Inspectorate and as Head of the Marketing Authorization. Her repertoire also covers experiences in international collaboration as former OIC–FDA International Affairs Office; media relations as former FDA Spokesperson; Quality Management System as former Quality Manager for the FDA Quality Management System on ISO 9001 initially for 2008 version and then 2015 version; on ASEAN Harmonization in the Healthcare Sector representing FDA PH as Head of Delegation or Delegate; on APEC as Delegate. Her publications include, among others, as lead author in several scientific articles published in peer-reviewed international journals (few accepted without correction) covering pharmaceutical science, chemometrics in drug formulation development (i.e. factorial designs, central composite designs) and liquid chromatography.

Speaker / Panelist

Choo Qiuyi

Regulatory Consultant
Health Sciences Authority



Dr Choo is a Regulatory Consultant with the Therapeutic Products Branch at the Health Sciences Authority (HSA), Singapore. Her work involves the pre-market scientific evaluation of therapeutic products, including critical assessment of pre-clinical and clinical data to support evidence-based regulatory decision-making. Through this work, she contributes to safeguarding public health by ensuring that therapeutic products meet established standards for quality, safety and efficacy.

Panelist

Shinichi Noda

Head, PMDA Asia Office
Pharmaceuticals and Medical Devices Agency (PMDA)



Shinichi NODA, Ph.D. is a regulatory professional specializing in regenerative medicine and stem cell biology. He earned his Ph.D. in Science in 2009 at the University of Tsukuba, based on his research on hematopoietic stem cells. At the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, he has been engaged in regulatory review, post-marketing safety activities, and international regulatory affairs, primarily related to cell and gene therapy products, from a regulatory authority perspective. Since April 2026, he has served as Head of the PMDA Asia Office, where he plays a bridging role between Japan and Asia, promoting regulatory harmonization and supporting the development of regulatory environments that facilitate smooth clinical development and improve access to innovative pharmaceuticals and medical devices across the Asian region.

Panelist

Athiporn Doomkaew

Pharmacist, Senior Professional Level
New Drug and Research Promotion Sub-Division
Food and Drug Administration
Ministry of Public Health, Thailand

Dr. Athiporn Doomkaew serves as a Senior Professional Pharmacist in the Medicines Regulation Division of the Thai Food and Drug Administration. Since 1997, she has specialized in the pre-marketing evaluation of new and generic drugs, including the rigorous assessment of quality dossiers.

Her extensive international experience includes active participation in ASEAN ACCSQ PPWG meetings and observations at ICH forums. Beyond her regulatory work, she is dedicated to advancing the field by mentoring pharmacy students and scientists. She holds a Ph.D. in Pharmaceutical Chemistry and Phytochemistry from Mahidol University, a Master of Pharmacy from Naresuan University, and a Bachelor of Pharmacy from Mahidol University.



Panelist

Ria Christine Siagian

Director of Drugs, Narcotics, Psychotropics, Precursors, and Addictive Substances Standardization
Indonesian Food and Drug Authority

ACADEMIC BACKGROUND

Doctor of Public Health, Universitas Indonesia. 2019
Master of Biopharmaceutical Science, The University of New South Wales, Sydney, Australia. 2006
Pharmacist, Universitas Indonesia, Depok, Indonesia. 1997.
Bachelor in Pharmacy, Universitas Indonesia, Depok, Indonesia. 1996.



WORKING EXPERIENCE

September 2025 – date

- Director, Directorate of Standardization for Drugs, Narcotics, Psychotropics, Precursors, and Addictive Substances, Badan Pengawas Obat dan Makanan (BPOM) / Indonesian Food and Drug Authority

May 2023 – September 2025

- Director, Directorate of Drug Registration, BPOM

March 2023 – May 2023

- Acting Director, Directorate of Standardization of Traditional Medicines, Health Supplement, and Cosmetics, BPOM

2019 – date

- Lecturer, Universitas Indonesia
- Reviewer, Q1-Q2 journals (Heliyon, IJHG, IJPHM, QHR, TLO, WHMP)

1999 – 2023.

- Evaluator Medical Products Registration, BPOM

ACHIEVEMENT

2019, Highly Commended Award, International Journal of Health Governance
2019, A cum laude distinction, Universitas Indonesia
2019, Second best student, Faculty of Public Health, Universitas Indonesia

Panelist

Rosliza Lajis

Deputy Director

Centre of Product and Cosmetic Evaluation, National of Pharmaceutical Regulatory Agency (NPRA)
National of Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia



Rosliza binti Lajis holds a Master of Science in Pharmacoeconomics and Health Economics from the University of Cardiff, United Kingdom. She has over 23 years of experience in the pharmacy field and currently serves as Deputy Director of the Centre for Product and Cosmetic Evaluation at the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia.

She oversees the regulatory evaluation of new drug products and contributes to the development of regulatory initiatives such as the Facilitated Registration Pathway and ASEAN Joint Assessment, with a focus on reliance-based approaches.

Rosliza also represents Malaysia in international regulatory collaborations and is committed to strengthening regulatory systems while ensuring the safety, quality, and efficacy of medicines.

Panelist

Siew Mei Long

Regulatory Affairs Director
MSD/PhAMA



Siew Mei, Long is presently the Regulatory Affairs Director and Country Lead at MSD Malaysia, bringing over two decades of experience within the pharmaceutical regulatory industry. As an active participant in APAC RA-EWG initiatives, Siew Mei has co-authored two significant APAC publications: “Asia Partnership Conference of Pharmaceutical Associations (APAC) Report on Regulatory Agility Implemented During the COVID-19 Pandemic: Inspiring Partnerships and Recommendations for the Way Forward” published in TIRS in September 2022, and “Advancements in Regulatory Agility, Regional Collaboration and Digital Transformation: Insights from the Asia Partnership Conference of Pharmaceutical Associations (APAC)” featured in AAPS in December 2024. Most recently, in July 2025, Siew Mei represented PhAMA as a panelist on Reliance at the Malaysia-Japan Symposium (MJS) held in Kuala Lumpur. Beyond her professional achievements, Siew Mei completed the Women’s Leadership Programme at Cornell University, USA, in 2021 and is a registered pharmacist with the Pharmacy Board of Malaysia.

DA Session

Overview

DA-EWG Megumi Ikemori

Reflecting on DA-EWG Contributions and Achievements

Our Journey: Comprehensive Review and Strategic Outlook

DA-EWG was active from 2013 to 2024, spanning twelve years, with the objective of fostering collaboration in drug discovery across Asia and contributing to the creation of innovative medicines. During this period, the landscape of Asian drug discovery changed significantly. Japan was no longer the sole central driver, and an increasing number of pharmaceutical companies began expanding into Asia independently. As a result, the incentive for companies to engage in Asia-focused drug discovery through an industry-wide framework diminished, and participation in DA-EWG declined substantially from its peak. This made it increasingly difficult to sustain the working group's activities.

At the same time, the strategic importance of drug discovery collaboration in Asia has continued to grow, as emphasized in the Japanese government's Global Health Vision released in August 2024. In response to these circumstances, DA-EWG decided to review its role and transfer its ongoing activities to the Research and Development Committee, its overseeing body. DA-EWG will therefore be disbanded in a constructive and forward-looking manner.

This DA-EWG session will provide a comprehensive review and assessment of the group's activities, including changes in participating organizations and members and achievements relative to its original objectives. Key topics such as the Natural Product Drug Discovery Consortium, the Japan–Taiwan network system DSANA, and microbiome research will be highlighted as examples of Asian drug discovery collaboration. Through this retrospective, participants are encouraged to reconsider the evolution of collaboration in Asia and reflect on its future potential.

Chair / Speaker

Megumi Ikemori

APAC DA-EWG leader
Senior Manager
Deep Human Biology Learning
Eisai Co Ltd.



Megumi Ikemori, Ph.D. has been a member of DA-EWG from 2018 and serves as the leader of APAC DA-EWG since 2022.

She is the Chairperson of the Research and Development(R&D) Subcommittee, R&D Committee, Japan Pharmaceutical Manufacturers Association (JPMA).

She currently belongs to DHBL Integrity & Site Management in Eisai Co., Ltd. as senior manager. In 2014, she received a doctorate in pharmacy from Gifu Pharmaceutical University. She has over 30 years of experience in the structure-based drug design (SBDD/CADD) and X-ray crystal structure analysis. She has the experience in drug discovery research using natural products, so she contributed to the activities of the Natural Product Drug Discovery Consortium (ANPDC)

Speaker

Jun Terauchi

JPMA DA-EWG member
Steering Committee Chair, Japan Microbiome Consortium (JMBC)
Chief Scientific Officer, Metagen Therapeutics Inc.



EDUCATION

1986-1991 Kyoto University, The Graduate School of Engineering (Kyoto, Japan)

WORK EXPERIENCE

2022 - present Chief Scientific Officer Metagen Therapeutics Inc.
2017 - present Steering Committee Chair, Japan Microbiome Consortium
2014 – 2022 Ono Pharmaceutical Co. Ltd.
1991 – 2013 Takeda Pharmaceutical Company Ltd.

Jun Terauchi, Ph.D. has been a member of DA-EWG since 2014. He contributed to create the Drug Seeds Alliance Network Asia, DSANA in the DA-EWG. He has more than 30 years' experience in drug discovery field. He also serves as the Steering Committee Chair at Japan Microbiome Consortium, since 2017. He was awarded the Dr. Tisser's Medal of The Intestinal Microbiology Society in 2024.

e-labeling Session

Overview

e-labeling-EWG Rie Matsui

Empowering Patients Through e-labeling: Bridging Digital Health and Accessible Information

As digital health continues to evolve, e-labeling has become a key enabler for healthcare professionals and patients by improving access to timely, accurate, and user friendly product information. This session will provide an update on the continued advancement of e-labeling initiatives across the APAC region, highlighting both current progress and future directions. Speakers from BPOM, NPRA, and the Taiwan FDA will share their regulatory perspectives and ongoing efforts to implement e-labeling frameworks within their jurisdictions. The session will also explore the development of e-labeling based on internationally harmonized standards, with a focus on ensuring interoperability with digital healthcare systems and enabling seamless integration into broader digital health ecosystems. During the panel discussion, the speakers will be joined by representatives from HSA, PMDA, the Philippines FDA(TBD), DAV(TBD), CDSCO, the Thai FDA, and MFDS to exchange views on regulatory expectations, implementation challenges, and lessons learned. Particular emphasis will be placed on how e-labeling can support future healthcare systems and empower patients by improving access to information, enhancing usability, and promoting more effective use of health information across diverse care settings. By strengthening regional collaboration and alignment with global standards, this session aims to explore how e-labeling can serve as a bridge between digital health innovation and accessible, patient centric product information—ultimately contributing to more informed healthcare decisions and improved patient outcomes across the APAC region.

Chair

Chih-Kang Chiang

Director-General
Taiwan Food and Drug Administration, Ministry of Health and Welfare



PERSONAL EXPERIENCES

- 2025/2/27~ Director General, TFDA, MOHW, Taiwan (R.O.C.)
- 2022/8~2025/2/26 Attending Physician and Director, Hemodialysis Division, Department of Integrated Diagnostic and Therapeutics, National Taiwan University Hospital
- 2024/8~2025/2/26 Professor and Director, Graduate Institute of Toxicology, College of Medicine, National Taiwan University
- 2023/8~2025/2/26 Deputy Vice President, Office of Academic Affairs, National Taiwan University
- 2023/8~2025/2/26 Director, Center for Teaching and Learning Development, National Taiwan University
- 2023/2~2025/2/26 Member, Food Safety Board, Executive Yuan, Taiwan

EDUCATION

- Ph.D. Graduate Institute of Toxicology,
- M.S. College of Law, National Chengchi University
- M.S. Graduate Institute of Clinical Medicine, National Taiwan University
- M.D. School of Medicine, Chung Shang Medical University

Dr. Chiang has been the Director General of the Taiwan Food and Drug Administration (TFDA) since February 27 2025. He oversees the regulation of food, drugs, medical devices, and cosmetics. Prior to the DG of TFDA, Dr. Chiang was a highly accomplished professional serving as the Director and attending Physician in the Section of Blood Purification, Department of Integrated Diagnostics & Therapeutics at NTUH, and a Professor and Director at the Graduate Institute of Toxicology at NTUH. With a distinguished academic background, Dr. Chiang obtained his PhD from the Graduate Institute of Toxicology at NTU in 2006. He further pursued postdoctoral training at the University of Tokyo, focusing on endoplasmic reticulum stress and hypoxia-related cellular mechanisms. Dr. Chiang's professional interests primarily revolve around internal medicine, kidney diseases, metabolic syndrome, pharmacology, toxicology, and risk analysis of food safety. With extensive expertise in these areas, he contributes significantly to the related fields.

Chair / Speaker

Rie Matsui

APAC e-labeling-EWG leader

Senior Director, Regional Head for APAC, International Labeling & Artwork, Global Regulatory Sciences, Pfizer R&D Japan



Rie Matsui is Senior Director, Regional Labeling Head for APAC, International Labeling Group, Global Regulatory Science, Pfizer Japan. She is also the Head, External Engagements for ILG and the co-chair for Pfizer E-labeling Centre of Excellence (ELCOE). She is the founder of Asia Labeling Hub at Pfizer that has created various local label updates for more than 25 countries in Asia. She is the lead for the APAC e-labeling Expert Working Group and the program chairperson for DIA Global Labeling Conference in 2025. She received the DIA Japan Regional Award in 2015. Her papers were published in scientific journals such as Therapeutic Innovation & Regulatory Science. She was the vice chair of the 2021 DIA Japan Annual Meeting Program Committee and is the vice chairperson for the DIA Advisory Council of Japan since July 2024. She received DIA Global Inspire Award Connector in 2022. She teaches at Keio University and Chiba University and is a pharmacist.

Speaker

Erlina Widianty Pratiwi

Senior Pharmaceutical and Food Safety Specialist
Indonesia FDA (Badan POM)



Erlina Widianty Pratiwi is a Senior Pharmaceutical and Food Safety Specialist at the Indonesia FDA (Badan POM). She has extensive experience in pharmaceutical regulation, focusing on improving access to medicine information and strengthening regulatory systems.

She is actively involved in digital health initiatives, including the e-labeling pilot project in Indonesia, supporting the adoption of international standards to enhance interoperability across healthcare systems.

Through her role, she contributes to improving patient access to reliable information and promoting the safe and effective use of medicines. She is also responsible for monitoring drug information, including the evaluation of medicine advertisements and labeling in the market.

Speaker

Kobu Thiruvanackan

Head of ICT Section
National Pharmaceutical Regulatory Agency, Malaysia



1. Professional background

- B.Pharm (Hons) University of Malaya, M.I.S. (Hons) National University of Malaysia (Faculty Outstanding Achievement Award).
- Certified Google Workspace Trainer.
- Gemini AI@Work Champion & AI Aware Badge (AI untuk rakyat).
- Google Cloud Technical Series (App Dev & Infrastructure Ed.) – Google Cloud APAC.
- Google & AWS Cloud Fundamentals Certified.

2. Notable roles or achievements

- Spearheaded NPRA ICT Section for 8 years. (22 years in Public Service)
- Led NPRA to win the Google Workspace Highest Uptake Usage award among Government Sector Agencies in 2023.
- Vast pharmacy background: Government Health Clinics (Sabak Bernam, Shah Alam Sec 7 & 19), Klang General Hospital, Pharmacy Practice & Development (Quality Use of Medicine), and NPRA (ICT Section).
- Extensive experience in digital transformation initiatives.
- Involved in major initiatives/policies: DUNAS, PTTS, MDC, Medicine Shortage & Discontinuation, ARPA, e-Labeling, and Patent-linkage.
- Publications/Speaking: Participated at the 77th FIP World Congress (Korea, 2017). Co-authored studies on { MTM (2007), Generic Medicine Awareness Guideline (2013), mHealth Evaluation (2017), Halal Capsule Shells (2018), and Generic Product Application Deficiencies (2024)}.

3. Current focus or interests

- Leading NPRA's digital transformation via QUEST 5 to enhance pharmaceutical regulatory services.

Speaker

Miao-Ju Chien

Associate Researcher
Medicinal Products/ Taiwan Food and Drug Administration (TFDA)



Education

Master of Science in Toxicology, National Taiwan University, Taiwan (2015)
Bachelor of Pharmacy, Kaohsiung Medical University, Taiwan (2010)

Experience

Associate Researcher, Division of Medicinal Products, TFDA (2025-Present)
Specialist, Division of Medicinal Products, TFDA (2025)
Associate Technical Specialist, Division of Medicinal Products, TFDA (2018-2025)

Miao-Ju Chien is a pharmacist specializing in pharmaceutical regulation and drug policy. She has over seven years of experience at the Taiwan Food and Drug Administration (TFDA). She has been actively involved in the development and implementation of e-labeling, including system establishment and regulatory promotion. Currently, she oversees and coordinates e-labeling initiatives to support the digital transformation of drug information in Taiwan.

Speaker

Miki Ota

Director, Office of Informatic and Management for Safety
Pharmaceuticals and Medical Devices Agency (PMDA)

Ms. Ota joined the Ministry of Health, Labour and Welfare (MHLW) in 2000. After joining the ministry, She has been involved in wide range of experience in public health field especially pharmaceutical administration, including pharmacovigilance.

She worked in several organizations including the Ministry of the Environment, PMDA, National Personnel Authority,

This is her second assignment to PMDA. During her previous assignment, She gained experience in the review of pharmaceuticals and medical devices.

Since April 2024, She has been working as the current position.



Panelist

Nguyen Van Loi

Head of the Drug Registration Division
Drug Administration of Vietnam (DAV), Ministry of Health

Dr. Nguyen Van Loi is currently the Head of the Drug Registration Division at the Drug Administration of Vietnam (DAV), Ministry of Health. With over 30 years of experience in the pharmaceutical sector, he possesses extensive expertise in laboratory testing, quality management, and drug registration. Prior to his current appointment, he held key leadership positions as Head of the Drug Quality Control Division and Head of the Cosmetics Management Division. In addition to his regulatory career, Dr. Loi previously served as a Lecturer in the Department of Biochemistry at the Hanoi University of Pharmacy. He earned his Bachelor of Pharmacy in 1990 and his PhD in Pharmaceutical Sciences in 2002, both from the Hanoi University of Pharmacy.



Panelist

Nada Kim

Assistant Director
Ministry of Food and Drug Safety

Nada Kim is a pharmacist by training and a pharmaceutical regulator at the Ministry of Food and Drug Safety (MFDS), Republic of Korea. She works on the development and implementation of regulatory policies related to pharmaceutical labeling, with a focus on improving patient-centered information and advancing digital approaches to product information.

She has been involved in advancing e-labeling initiatives in Korea, including the development of guidelines to enhance accessibility, readability, and integration with digital health systems. She is also actively engaged in international regulatory collaboration through organizations such as WHO and PIC/S, contributing to global harmonization efforts in various regulatory areas.



Panelist

Kharlo De Guzman

Food-Drug Regulation Officer III
Food and Drug Administration Philippines

Kharlo de Guzman is a Food-Drug Regulatory Officer at the Product Research and Standards Development Division of the Center for Drug Regulation and Research, FDA Philippines. He is actively involved in policy development, with a primary focus on strengthening drug product regulation. In his current role, he contributes to enhancing pharmaceutical regulatory frameworks through the development of new policies and the review and refinement of existing FDA issuances.

Prior to this, he served in the Vaccine and Biological Unit of the FDA Philippines' Common Services Laboratory, where he played a key role in the technical evaluation and procedural development for the National Lot Release of vaccines and biological products. He also demonstrated expertise in laboratory analysis for pharmaceuticals and medical devices, supporting quality and safety assurance.



Panelist

Worasuda Yoongthong

Director of Medicines Regulation Division
Food and Drug Administration
Ministry of Public Health, Thailand

Ms. Worasuda Yoongthong is Director of the Medicines Regulation Division at the Thai Food and Drug Administration, with over 30 years of experience in health product regulatory control. She previously served as Director of the Food Control Division and played significant role in formulating Thailand's National List of Essential Medicines.

She has extensively participated in numerous international and regional activities, including the WHO Expert Committee on Essential Medicines, ASEAN Harmonization, APEC and ICH as an observer.

She currently serves as the Thai FDA Head of Delegation (HOD) in the Pharmaceutical Product Working Group (PPWG) and contributed to establishing Thailand's abbreviated drug licensing pathway in 2018.

Ms. Yoongthong holds a Bachelor's degree in Pharmaceutical Sciences from Prince of Songkla University, Thailand, and a Master of Science in Epidemiology from Harvard University, USA.



Panelist

Shimon Yoshida

Head of International Labeling & Artwork, , Global Regulatory Sciences
Pfizer

Dr. Shimon Yoshida has worked in the pharmaceutical industry for over 25 years in a number of positions across pharmacovigilance, clinical development, medical writing and regulatory affairs. He is currently on the International Advisory Board for the IMI Gravitare Health project for electronic product information (ePI). Shimon heads the International Labeling and Artwork group in Pfizer, responsible for all local labeling documents for Pfizer's medicines around the world and the associated artwork change control processes.



Dorothy Toh

Assistant Group Director
Health Sciences Authority

Dr Dorothy Toh is the Assistant Group Director of the Medicinal Products Pre-market Cluster at the Health Products Regulation Group, Health Sciences Authority. Her responsibilities include providing leadership and directing the operations to ensure that clinical trials are approved and conducted in accordance with regulatory requirements and health products are regulated to meet appropriate standards of safety, quality and efficacy.



Dorothy has won several awards for her achievements in both public service and scientific arenas. During the COVID-19 pandemic, she co-led the development of Biologics Testing capability and won the Dare to Do Public Service Transformation Awards. Her team was awarded the Inaugural Mrs Tan Shook Fong – Pharmaceutical Society of Singapore Innovative and Scientific Research Award, for successfully implementing new testing protocols that reduced serious adverse events to certain medicines.

MQS Session

Overview

MQS-Task Force Keiichi Kodama

Advanced Technologies

Advanced Technologies including Artificial Intelligence, Machine Learning, and 3D Printing have become a hot topic in the pharmaceutical industry. Their effective utilization is expected to support innovation for the benefit of patients. To maximizing the patient's benefit by Advanced Technologies, we are now facing some challenges and difficulties. Draft guideline of new PIC/S Annex 22 "Artificial Intelligence" and draft guideline revised PIC/S Annex 11 "Computerized Systems" had been published, and the detailed discussion would be implemented by authorities, industries and academia. In the session, we introduce the latest situation of the preparation of the actions in the authorities and industries including PIC/S Annex 22 preparation, the use case of Advanced Technologies in the industry and such framework. We aim to foster momentum for effective use of Advanced Technologies in Asia by increasing understanding of Advanced Technologies among regulators and industry, and by newly established relevant guidelines that have been developed.

Chair / Speaker

Nobuhiro Shimizu

Inspector
Office of Manufacturing Quality for Drugs
Pharmaceuticals and Medical Devices Agency (PMDA)



Mr Nobuhiro Shimizu has the following experience:

- 7 years of experience in quality assurance and regulatory affairs at a manufacturer of biologically derived medical devices.
- 4 years of experience in facility start-up within the engineering department of a contract manufacturing organization (CMO) producing ATMPs.
- 3 years of experience at the PMDA, Japan, currently serving as a Lead Inspector for biological and aseptic products.

Chair

Keiichi Kodama

Senior Director, Japan Quality Systems Group, Tokyo District Department,
Japan Regional Quality
Eisai Co., Ltd.



I have 21 years of experience at manufacturing, quality control and quality assurance department in API plant of Eisai Co., Ltd. I moved to quality assurance department of head quarter in 2025. And, I'm a member of Quality and Technology Committee of Japan Pharmaceutical Manufacturing Association (JPMA) and APAC MQS-TF leader since 2025.

Speaker / Panelist

Ikuo Kushida

Director, CMC Regulatory
Eisai Co. Ltd.

Dr. Ikuo Kushida is a member of the APAC MQS Task Force and currently serves in CMC Regulatory Affairs at Eisai Co., Ltd. He began his career at Eisai as a research scientist, where he conducted non-clinical studies in pharmacokinetics and drug metabolism, followed by pre-formulation research. He subsequently specialized in physical chemistry within the field of analytical research, gaining extensive experience in analytical method development, drug candidate screening, and characterization of crystal polymorphism.

Since 2021, Dr. Kushida has been engaged in CMC regulatory affairs, applying his multidisciplinary scientific expertise to support regulatory strategy and quality-related activities across the APAC region.



Speaker / Panelist

Lim Na

Director
Health Sciences Authority

Ms Lim Na serves as the Director of the Licensing and Certification Branch at Health Sciences Authority (HSA). She joined HSA in 2003 and currently oversees key regulatory functions including GMP certification, the import and export licensing of controlled drugs and psychotropic substances, and the issuance of Certificate of Pharmaceutical Product (CPP) and Free Sale Certificate (FSC). Beyond her operational responsibilities, she helps shape strategy formulation and policy development for the regulatory and licensing framework governing health products, and conducts GMP inspections.

In the area of advanced technologies, Ms Lim Na represents HSA as a topic lead in the expert working group responsible for the development of ICH Q13 on Continuous Manufacturing of Drug Substances and Drug Products, and contributes to the development of associated training materials to support its implementation.



Speaker / Panelist

Srinivasan Kellathur

CMC Regulatory Policy Lead APAC
Hoffmann-La Roche Singapore

Dr Srinivasan KELLATHUR is currently the Regulatory Policy Lead for APAC at Hoffmann-La Roche based in Singapore. He drives regulatory convergence initiatives with a focus on CMC topics and ensures the implementation of reliance pathways across the region. Prior to joining Roche, Srini was with the Health Sciences Authority, Singapore where he headed the Advanced Therapy Products Branch, responsible for policy and legislation and implementation of cell, tissue, and gene therapy products regulations, the first country in ASEAN to provide a comprehensive regulation. Srini represents the Biotechnology Innovation Organisation as a sub-champion to promote regulatory convergence for advanced therapy products in APEC. He leads the cell and gene therapy (CGT) workstream at IFPMA in promoting global regulatory convergence. He was also the IFPMA CGT Taskforce Expert, representing the Singapore Association of Pharmaceutical Industries, to support its activities at the ICH CGT Discussion Group. Srini sits on several international groups: APAC Regenerative Medicine forum, International Society for Cellular Therapy APAC Industry Committee, member of The European Federation of Pharmaceutical Industries and Associations regional networks – ASEAN, Korea-Taiwan and India.



Panelist

Kentaro Hara

Office Director
Office of Manufacturing Quality for Drugs
Pharmaceuticals and Medical Devices Agency (PMDA)

Dr. Kentaro HARA has 18 years of experience in PMDA Japan, including 3 years as a CMC reviewer and 15 years as a GMP inspector. He conducted many on-site GMP inspections in India, China and other countries. He was a member of ICH Q7 IWG, ICH Q12 EWG and PIC/S Executive Bureau (2022-2025).

Next ten years, he will work to further strengthen cooperation in PIC/S participant authorities and improve GMP Inspection Reliance in the Asia Pacific region. Technical background is bioscience.



Speaker / Panelist

Yuki Marumo

Inspector
Office of Manufacturing Quality for Drugs
Pharmaceuticals and Medical Devices Agency (PMDA)

Mr. Yuki MARUMO has 7 years of experience in PMDA, Japan, including 4 years as an Office of Review Management and 3 years as a GMP inspector. He mainly conducted on-site inspections API manufacturing sites such as in India, China and other countries. He also works international collaboration including PIC/S related activities and shared our department's activities and perspective on "Advanced technologies in pharmaceutical manufacturing" at the PIC/S seminar in Hong Kong. He has been a member of PIC/S Drafting group of Annex 11 and 22 since last November.



aUHC Session

Overview

aUHC-EWG Osamu Kagawa

Realizing True UHC in Asia through Hybrid Financing Models

As public healthcare systems across Asia face growing financial pressures and reach their fiscal limits, achieving sustainable Universal Health Coverage (UHC) requires innovative financing. This year's aUHC session focuses on "Bridging the Funding Gap" by exploring hybrid models that effectively integrate private resources to supplement core public systems.

The session highlights three key approaches from rapidly evolving Asian healthcare systems:

- **India:** Highlighting policy reforms and tax incentives designed to stimulate private investment and expand health insurance coverage.
- **China:** Showcasing successful Public-Private Partnership (PPP) models and supplementary insurance to secure sustainable access to high-cost innovative medicines.
- **Taiwan:** Positioning UHC as a vital social infrastructure that drives "Health Equity" to address broader societal challenges, including an aging population.

Through an interactive panel discussion, the session aims to build a consensus on the necessity of a "Hybrid Model". By leveraging policy reforms, structured PPPs, and a commitment to health equity, healthcare systems across Asia can secure the sustainable financing needed to deliver timely, innovative treatments to patients.

Chair / Speaker

Toshihiko Takeda

Former Director-General, Health Policy Bureau.
The Ministry of Health, Labour and Welfare (MHLW), Japan

Current Position
Senior Advisor, Boston Consulting Group
Visiting Professor, Iwate Medical University
Advisor, Nishimura & Asahi



Toshihiko Takeda joined the Ministry of Health and Welfare (MHW) in 1983, immediately after his graduation from the Tokyo University. His experience in the Ministry covers health policy, health insurance policy, industrial policy for health industries, and overall social security policy. He also served as a director with JETRO New York Center, working for health care industry.

He worked as the Deputy Director-General of Health Insurance Bureau in 2014-15, the Director-General of Policy Planning for Social Security System in 2015-16 and the Director-General of Pharmaceutical Safety and Environmental Health in 2016-2017, he was appointed as the Director-General of Health Policy Bureau in July 2017, then retired in 2018.

He joined the Boston Consulting Group in 2019.

Speaker / Panelist

G. N. Singh

Advisor to Hon'ble Chief Minister, Government of Uttar Pradesh, India; & Former Drugs Controller General (India)

Government of Uttar Pradesh, India

Dr. Gyanendra Nath Singh is a distinguished regulatory leader and former Drugs Controller General (India) from Feb 2012 to 2018, who played a pivotal role in strengthening India's drug regulatory framework.



He currently serves as Healthcare & Pharma Advisor to the Hon'ble Chief Minister, Uttar Pradesh, India.

As the Founder Director of the Indian Pharmacopoeia Commission, he led the development and expansion of national drug standards, significantly enhancing their global recognition.

He spearheaded major capacity-building initiatives for regulatory systems in India and contributed to positioning CDSCO as a globally recognized stringent regulatory authority.

Dr. Singh has over 139 scientific publications and extensive contributions to pharmaceutical education and research, and is an empaneled expert with WHO and UNIDO, continuing to shape India's healthcare ecosystem.

Speaker / Panelist

Alex Xia

General Manager

Shanghai Shuisai Technology Co., Ltd.

Over 20 years of professional experience at global healthcare companies including 3M, Roche, BMS and MSD, with responsibilities spanning sales, marketing and market access.

Since 2010, I have focused on building partnerships between commercial insurance (and other financial institutions) and the healthcare industry. Starting from China, my work has extended across the Asia-Pacific and global markets. Over the past 15 years, I have successfully launched and implemented innovative payment solutions in multiple markets.

Founded Shuisai Technology in China in 2026, committed to building a bridge between the insurance industry and the pharmaceutical industry.



Speaker / Panelist

Lian-yu Chen

Director General
National Health Insurance Administration, Ministry of Health and Welfare



Education:

Ph.D., Bloomberg School of Public Health, The Johns Hopkins University, USA
M.D., National Cheng Kung University, Taiwan


Professional Experience:

- Deputy Director-General, National Health Insurance Administration, Ministry of Health and Welfare, 2024-2025
- Director-General, Department of Mental Health, Ministry of Health and Welfare, 2023-2024
- Adjunct Associate Professor, Graduate Institute of Clinical Medicine, College of Medicine, National Chung Hsing University, 2024-Present
- Adjunct Assistant Professor, Institute of Epidemiology and Preventive Medicine, School of Public Health, National Taiwan University, 2017-Present
- Member, College on Problem of Drug Dependence, USA, 2017-Present
- Director, Kunming Prevention and Control Center, Taipei City Hospital, 2021-2023
- Secretary-General, Taiwanese Society of Psychiatry, 2021-2023
- Council Member, Taiwanese Society of Addiction Science, 2020-2023
- Deputy Director, Kunming Prevention and Control Center, Taipei City Hospital, 2019-2021
- Secretary-General, Taiwanese Society of Addiction Science, 2018-2020
- Attending Psychiatrist, Division of Addiction Science, Taipei City Hospital, 2014-2019

Honors and Awards:

- Outstanding Alumni Award, College of Medicine of National Cheng Kung University, Taiwan, 2023
- Kyorin Award, Taipei Medical Association, Taiwan, 2022
- Certificate of the Symbol of National Quality, Taiwan, 2021
- National Anti-Drug Award, Taiwan, 2021
- Excellent Young Scholar of Ministry of Science and Technology, Taiwan, 2019-2021
- Best Thesis Award, Taiwanese Society of Addiction Sciences, Taiwan, 2016
- Distinguished Alumni Award of National Cheng Kung University, Taiwan, 2016
- Sartorius Award, 5th World Congress of Asian Psychiatry, 2015
- Phi Beta Kappa Award in Johns Hopkins Bloomberg School of Public Health, USA, 2014
- Lucy Shum Award, Johns Hopkins Bloomberg School of Public Health, USA, 2014
- Sommer Scholarship, Johns Hopkins Bloomberg School of Public Health, USA, 2012-2014
- Travel Award to Annual meeting of ISPE (International Society for Pharmacoepidemiology), 2014
- NIDA Women & Sex/Gender Junior Investigator Travel Award for meeting of the College on Problems of Drug Dependence (CPDD), 2012

APAC is an industry-driven initiative led by R&D-based pharmaceutical associations from Asian economies, aiming to fulfill its mission.



<https://apac-asia.com/>

